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U.S. Places Argentina On List Of Patent Right Violators
&amp; Considers Retaliatory Trade Sanctions
by Erika Harding
Category/Department:  General
Published:  Thursday, May 6, 1993
US officials say Argentina's failure to approve new laws that would protect the patents of US
pharmaceutical firms may soon lead to trade sanctions against that country. At the end of April,
the Office of the US Trade Representative placed Argentina along with Brazil and at least 15 other
countries around the world on a list of nations accused of either grossly violating US copyrights,
or of not properly respecting such rights. In particular, Japan, Brazil, India, and Thailand were
labelled "serious trade regulation offenders" for refusing to respect US patent rights, and for
imposing unfair trade barriers to imports of certain US products. Loopholes in Brazil's patent
laws which are based on a system of "first to file" rather than "first to invent" have allowed local
companies to legally "steal" brand names of established US companies, and then make hefty
profits reselling the copyrights to foreign firms who want to use their labels on the domestic market
(see Chronicle, 04/22/93). Although Argentina was not accused of such gross violations, the USTR
included that country on the list of nations that do not adequately respect patent rights. As a result,
Argentina will now be "closely watched" by US officials, whose investigations may eventually
lead to retaliatory trade sanctions if the government does not approve stricter patent laws. Under
the 1988 Omnibus Trade Act, once a country is placed on a list for observation, the USTR has
one month to decide whether to begin a formal investigation. If the investigation confirms patent
violations, then trade sanctions can be ordered against the abusing country. In Argentina's case,
an investigation is likely, since US trade officials say they hope to use Argentina to set an example
to other Latin American countries. "US companies have sufferred significantly in Argentina as
a result of lack of patent protection and the US Congress has made it very clear that we have an
obligation to do what is necessary to protect the interests of American companies abroad," one
high-level USTR spokesperson told the New York Times. "US firms are losing billions every year
from a lack of patent protection and this administration is intent on changing that. Moreover, for
countries like Argentina, strict patent laws that stop pirating should actually stimulate investment
there, something those countries say they are interested in." The crux of the conflict is pirating
of US-invented medicines by Argentine pharmaceutical firms, which US drug companies say are
costing them up to US$200 million per year in lost profits. According to US industry representatives,
the Argentine companies copying their goods charge much more for the final product than the
original multinational manufacturers in some cases up to 30% more which represents enormous
profits for the pirating firms since no research and development costs are involved. "The original
product needs 10 to 12 years of research and hundreds of millions of dollars in costs, and here
the imitations only require large sums of money for marketing," said Rafael Alonso, the director
of patents for the Argentine Chamber for Specialized Medicines, representing the multinational
companies. In addition, Alonso claims that quality control among Argentine companies is lax,
posing potential health risks to the public. In some cases, for example, drugs patented and tested by
US companies have been produced and placed on the shelves of Argentine pharmacies by pirating
companies even before the US manufacturer got approval to sell the drug in the US. Nevertheless,
efforts to pass tougher laws to protect foreign patents have so far been unsuccessful. President
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Carlos Menem's administration drafted a tough patent protection bill nearly two years ago, but
the initiative is completely stalled in Congress (see Chronicle 04/01/93). In fact, on April 28 the
Chamber of Deputies' Industry Commission voted to take the bill off its agenda in the present round
of "extraordinary sessions," meaning that the Menem administration will now have to completely
resubmit the initiative to Congress when the next period of "ordinary sessions" begins. That, in turn,
could signify another two- year process before the bill ever reaches the legislative floor. According
to US officials and firms, a powerful lobby by the local pharmaceutical companies which boast
of about US$2 billion in annual sales of medicines on the domestic market has influenced many
legislators against the bill. According to representatives of the national laboratories cited by the
New York Times, many of the foreign firms' accusations are slanderous. Rather than charge more
for their products than the US companies, for example, they claim their prices are, on the average,
about 8% to 9% lower. In addition, they stress that the multinationals were aware that the local
laws are different than in the US when they entered the Argentine market. An 1864 law protects
the manufacturing process, but not the final product. "We are not pirates, nor copiers, as we are
accused," said Anibal Caprile, president of Cilfa, the group of 17 Argentine companies lobbying
against the Menem administration's proposed patent bill. "We use a different process than the
original and arrive at the same final product, and that is permitted under our laws." (Sources:
Agence France-Presse, 04/28/93, 04/29/93; Deutsch Press Agentur, 04/30/93; New York Times,
05/03/93)
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